Publications by authors named "George Kapetsis"
Predictive biomarkers are necessary for the identification of immunotherapy-responsive patients. Tumor mutation burden (TMB), as determined by next-generation sequencing (NGS), and PD-L1 expression, as evaluated by Immunohistochemistry (IHC), are the biomarkers most frequently employed in clinical practice. In addition, microsatellite instability (MSI) was the first biomarker to demonstrate immunotherapy efficacy irrespective of the type of tumor and possesses a high predictive value.
View Article and Find Full Text PDFDigging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction.
Dimitrios C Ziogas Eirini Papadopoulou Helen Gogas Stratigoula Sakellariou Evangellos Felekouras George Kapetsis
Cancers (Basel)
December 2023
Article Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) has a very poor prognosis and limited treatment options, with a lack of comprehensive genomic data from large populations.
- In a study involving 409 Greek patients, a genomic analysis using next generation sequencing (NGS) revealed that common mutations were found in genes, with 81.50% of samples showing the most frequent mutation.
- The research also indicated potential treatment implications based on genomic findings, with an increase in possible benefit from NGS-oriented treatment from 1.91% to 13.74%, highlighting important characteristics and insights for PDAC in European patients.
Article Synopsis
- The study explores the effectiveness of PARP inhibitors in treating various cancers, focusing on the relationship between genomic loss of heterozygosity (gLOH) and gene alterations in patients.
- It analyzes 406 tumor samples using next-generation sequencing (NGS), highlighting that nearly 21% of tumors displayed homologous recombination (HR) variations, while about 5% had gene alterations.
- The findings suggest a strong correlation between high gLOH percentages and positive gene alterations, indicating that assessing gLOH could help identify more patients who may benefit from PARP inhibitors.